Beatrice J Edwards

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6176293/publications.pdf

Version: 2024-02-01

72 4,166 29 63
papers citations h-index g-index

73 73 73 73 5053

73 73 5053
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA - Journal of the American Medical Association, 2008, 299, 914.	7.4	657
2	Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2016, 31, 16-35.	2.8	491
3	Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. Journal of the American Dental Association, 2011, 142, 1243-1251.	1.5	317
4	Lateral Balance Factors Predict Future Falls in Community-Living Older Adults. Archives of Physical Medicine and Rehabilitation, 2008, 89, 1708-1713.	0.9	246
5	Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy. Journal of the American Dental Association, 2008, 139, 1674-1677.	1.5	141
6	Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncology, The, 2008, 9, 1166-1172.	10.7	131
7	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 2916-2946.	1.6	127
8	Functional decline after incident wrist fractures–Study of Osteoporotic Fractures: prospective cohort study. BMJ: British Medical Journal, 2010, 341, c3324-c3324.	2.3	110
9	Prior Fractures are Common in Patients with Subsequent Hip Fractures. Clinical Orthopaedics and Related Research, 2007, 461, 226-230.	1.5	103
10	Bisphosphonates and Nonhealing Femoral Fractures: Analysis of the FDA Adverse Event Reporting System (FAERS) and International Safety Efforts. Journal of Bone and Joint Surgery - Series A, 2013, 95, 297-307.	3.0	100
11	Age Influences the Outcome of a Slipping Perturbation During Initial But Not Repeated Exposures. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M496-M503.	3.6	86
12	BARRIERS AND SOLUTIONS TO OSTEOPOROSIS CARE IN PATIENTS WITH A HIP FRACTURE. Journal of Bone and Joint Surgery - Series A, 2003, 85, 1837-1843.	3.0	84
13	NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1357-1370.	4.9	82
14	Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?. Journal of Clinical Oncology, 2009, 27, 4398-4405.	1.6	81
15	Malnutrition and overall survival in older adults with cancer: A systematic review and meta-analysis. Journal of Geriatric Oncology, 2019, 10, 874-883.	1.0	81
16	One Step, Two Steps, Three Steps More … Directional Vulnerability to Falls in Community-Dwelling Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 1540-1548.	3.6	79
17	Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatric Radiology, 2014, 44, 173-180.	2.0	74
18	Own the Bone, a System-Based Intervention, Improves Osteoporosis Care After Fragility Fractures. Journal of Bone and Joint Surgery - Series A, 2016, 98, e109.	3.0	69

#	Article	IF	CITATIONS
19	Amiodarone-associated Optic Neuropathy: A Critical Review. American Journal of Medicine, 2012, 125, 447-453.	1.5	64
20	Malnutrition in Older Adults with Cancer. Current Oncology Reports, 2019, 21, 80.	4.0	64
21	Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study. Drug Safety, 2017, 40, 249-255.	3.2	57
22	Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. Journal of Bone and Mineral Research, 2016, 31, 1569-1576.	2.8	44
23	Evaluation of Serious Adverse Drug Reactions. Archives of Internal Medicine, 2007, 167, 1041.	3.8	43
24	Predicting Fracture Risk in Younger Postmenopausal Women: Comparison of the Garvan and FRAX Risk Calculators in the Women's Health Initiative Study. Journal of General Internal Medicine, 2019, 34, 235-242.	2.6	41
25	Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer. Clinical Cancer Research, 2011, 17, 560-568.	7.0	40
26	Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's adverse event reporting system and review of case reports in the literature. Expert Opinion on Drug Safety, 2014, 13, 15-23.	2.4	40
27	Addressing Secondary Prevention of Osteoporosis in Fracture Care: Follow-up to "Own the Bone― Journal of Bone and Joint Surgery - Series A, 2011, 93, e87.	3.0	35
28	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Research and Treatment, 2017, 164, 57-67.	2.5	31
29	Prevalence and factors associated with malnutrition in older patients with cancer. Journal of Geriatric Oncology, 2019, 10, 763-769.	1.0	31
30	An Osteoporosis and Fracture Intervention Program Increases the Diagnosis and Treatment for Osteoporosis for Patients with Minimal Trauma Fractures. Joint Commission Journal on Quality and Patient Safety, 2005, 31, 267-274.	0.7	30
31	Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis— a research on adverse drug events and reports (RADAR) report. British Journal of Radiology, 2014, 87, 20140307.	2.2	30
32	Risk factors for falls in older patients with cancer. BMJ Supportive and Palliative Care, 2018, 8, 34-37.	1.6	28
33	Malnutrition and overall survival in older patients with cancer. Clinical Nutrition, 2021, 40, 966-977.	5.0	28
34	Endocrinology of menopause. Periodontology 2000, 2013, 61, 177-194.	13.4	27
35	Osteoporosis and Its Implications for Dental Patients. Journal of the American Dental Association, 2008, 139, 545-552.	1.5	26
36	Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate. Clinical Cancer Research, 2009, 15, 3850-3855.	7.0	25

#	Article	IF	CITATIONS
37	Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes. Neurology, 2015, 85, 1131-1138.	1.1	25
38	Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project. Drugs in R and D, 2017, 17, 211-218.	2.2	22
39	Effects of Cancer Comorbidity on Disease Management: Making the Case for Diabetes Education (A) Tj ETQq1	1 0.784314 1.7	rgBT Overlo
40	The Association of the C-Reactive Protein Inflammatory Biomarker with Breast Cancer Incidence and Mortality in the Women's Health Initiative. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1100-1106.	2.5	20
41	Elevated incidence of fractures in women with invasive breast cancer. Osteoporosis International, 2016, 27, 499-507.	3.1	19
42	Overall survival in older patients with cancer. BMJ Supportive and Palliative Care, 2020, 10, 25-35.	1.6	19
43	Osteoporosis screening of postmenopausal women in the primary care setting: A case-based approach. Gender Medicine, 2004, 1, 70-85.	1.4	18
44	Acute Kidney Injury and Bisphosphonate Use in Cancer: A Report From the Research on Adverse Drug Events and Reports (RADAR) Project. Journal of Oncology Practice, 2013, 9, 101-106.	2.5	18
45	Acute vertebral fracture. Journal of Hospital Medicine, 2009, 4, E20-4.	1.4	17
46	Neurocognitive deficits in older patients with cancer. Journal of Geriatric Oncology, 2018, 9, 482-487.	1.0	17
47	Osteoporosis-related Vertebral Fragility Fractures. Spine, 2020, 45, E430-E438.	2.0	16
48	Results from the First Decade of Research Conducted by the Research on Adverse Drug Events and Reports (RADAR) Project. Drug Safety, 2013, 36, 335-347.	3.2	15
49	Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Supportive Care in Cancer, 2018, 26, 1561-1568.	2.2	14
50	Postmenopausal women with minimal trauma fractures are unapprised of the existence of low bone mass or osteoporosis. Maturitas, 2006, 53, 260-266.	2.4	12
51	Osteoporosis Risk Calculators. Journal of Clinical Densitometry, 2017, 20, 379-388.	1.2	12
52	Resection of granulomatous tissue resolves silicone induced hypercalcemia. Bone Reports, 2016, 5, 163-167.	0.4	11
53	Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. Journal of Geriatric Oncology, 2018, 9, 81-83.	1.0	11
54	The validity of three malnutrition screening markers among older patients with cancer. BMJ Supportive and Palliative Care, 2020, 10, 363-368.	1.6	10

#	Article	IF	CITATIONS
55	Adverse Effects of Drugs Used to Treat Hematologic Malignancies: Surveillance Efforts from the Research on Adverse Drug Events and Reports Project. Seminars in Thrombosis and Hemostasis, 2007, 33, 365-372.	2.7	9
56	Comparison of the Sensitivity of a Pre-MRI Questionnaire and Point of Care eGFR Testing for Detection of Impaired Renal Function. Academic Radiology, 2012, 19, 1181-1185.	2.5	9
57	Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs. Expert Opinion on Drug Safety, 2013, 12, 299-307.	2.4	9
58	Reporting of serious adverse events during cancer clinical trials to the institutional review board: An evaluation by the $\langle i \rangle R < i \rangle e$ gearch on $\langle i \rangle A < i \rangle d$ verse $\langle i \rangle D < i \rangle rug$ events $\langle i \rangle A < i \rangle R < i \rangle e$ ports (RADAR) project. Journal of Clinical Pharmacology, 2013, 53, 1334-1340.	2.0	8
59	Incorporating Geriatric Medicine Providers into the Care of the Older Adult with Cancer. Current Oncology Reports, 2016, 18, 65.	4.0	8
60	Online Educational Tool to Promote Bone Health in Cancer Survivors. Journal of Health Communication, 2017, 22, 808-817.	2.4	7
61	Women with wrist fractures are at increased risk for future fractures because of both skeletal and non-skeletal risk factors. Age and Ageing, 2006, 35, 438-441.	1.6	6
62	Solutions to the Undertreatment of Osteoporosis-Related Fractures. Archives of Internal Medicine, 2004, 164, 677.	3.8	2
63	Als: implications for fractures in perimenopausal women with breast cancer. Community Oncology, 2008, 5, 625-626.	0.2	1
64	Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear. Blood, 2008, 112, 2403-2403.	1.4	1
65	Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe Blood, 2009, 114, 4538-4538.	1.4	1
66	Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive. Blood, 2012, 120, 4692-4692.	1.4	1
67	Pharmacovigilance and reporting of bisphosphonate use and osteonecrosis of the jaw. Community Oncology, 2007, 4, 633-634.	0.2	O
68	Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project Blood, 2007, 110, 3339-3339.	1.4	0
69	Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR). Blood, 2008, 112, 4662-4662.	1.4	O
70	Novel risk factors for osteonecrosis of the jaw in multiple myeloma: A RADAR report Journal of Clinical Oncology, 2012, 30, 6623-6623.	1.6	0
71	Association of breast cancer in men with exposure to $5 \cdot \hat{l}_{\pm}$ reductase inhibitors: A RADAR report Journal of Clinical Oncology, 2012, 30, 2532-2532.	1.6	O
72	Bisphosphonates and esophageal cancer: A RADAR report Journal of Clinical Oncology, 2012, 30, 4063-4063.	1.6	0